<DOC>
<DOCNO>
EP-0007294
</DOCNO>
<TEXT>
<DATE>
19800123
</DATE>
<IPC-CLASSIFICATIONS>
A61P-9/04 A61P-11/00 A61K-31/138 C07C-41/00 C07C-213/00 C07C-217/34 C07C-255/54 A61K-31/135 A61P-9/08 A61K-31/13 C07C-217/00 A61K-31/275 C07C-67/00 C07C-43/00 C07C-41/26 C07C-43/23 C07C-217/32 C07C-253/00 C07C-255/00 C07C-43/205 A61P-9/00 A61P-11/08 A61P-9/12 A61P-9/06 A61P-9/10 
</IPC-CLASSIFICATIONS>
<TITLE>
membrane stabilizing compounds having beta-receptor blocking activity, their preparation, method for treatment of arrhythmic conditions, and pharmaceutical preparations containing same
</TITLE>
<APPLICANT>
haessle abse<sep>aktiebolaget hassle  <sep>aktiebolaget hässlekärragatan 5s-431 83 mölndalse<sep>
</APPLICANT>
<INVENTOR>
aberg axel karl gunnarus<sep>byrnes eugene williamus<sep>samuelsson gustav benny rogerse<sep>aberg, axel karl gunnar<sep>byrnes, eugene william<sep>samuelsson, gustav benny roger<sep>aberg, axel karl gunnar12 sherburne roadvestboro, massachusetts 01581us<sep>byrnes, eugene william191 nola driveholden, massachusetts 01520us<sep>samuelsson, gustav benny rogertubavägen 1 bs-435 00 mölnlyckese<sep>
</INVENTOR>
<ABSTRACT>
the present invention relates to new potent membrane stabilizing compounds of the formula <chem> wherein r<1> is alkoxyalkyl, hydroxyalkyl or alkyl, which alkyl groups may be branched or straight, r<2> is halogen or hydrogen, r<3> is hydrogen or alkyl, r<4> and r<5> are same or different and are each hydrogen, alkoxy, alkyl, alkoxyalkyl, cyano, or hydroxy, n is 0, 1, 2, or 3, and x is -o-, -ch2-, or @     the present compounds are potent heart antiarrhythmic agents possessing membrane stabilizing effect and  beta -receptor blocking effect in same clinical doses.  the compounds are used in treating antiarrhythmic conditions, but can also be used in the treatment of hypertension, angina pectoris, or nervous heart.  the invention also relates to processes for preparing the compounds, method of treating antiarrhythmic conditions and pharmaceutical preparations containing said compounds. 
</ABSTRACT>
<DESCRIPTION>
membrane stabilizing compounds having ss-recaptor blocking activity, their preparation, method for treatment of arrhythmic conditions, and pharmaceutical preparations containing same the present invention relates to new potent membrane stabilizing compounds es well as their preparation and a method for treating symptoms and signs of arrhythmic conditions by stabilizing membranes of the heart, hypertension, angina pectoris, nervous heart, by administering to mammals, including man, these new compounds. the new compounds are those of the general formula emi1.1 wherein r1 is selected from the group consisting of alkoxyalkyl, hydroxyalkyl and alkyl, which alkyl groups may be branched or straight, r2 is selected from the group consist- ing of halogen and hydrogen, r3 is selected from the group 4 consisting of hydrogen and alkyl, r4 and r5 are the same or different and are each selected from the group consisting of hydrogen, alkoxy, alkyl, alkoxyalkyl, cyano, and hydroxy, n is an integer 0,1 2, or 3, and. x is -0-, -ch2, or emi2.1 whereby n is not zero when x is oxygen. the alkoxyalkyl r1 has up to 4 carbon atoms in each alkyl part, whereby each alkyl part may be branched or straight, and is, e.g., methoxymethyl, 2-methoxyethyl, 1-methoxyethyl, 3-methoxypropyl, 2-methoxypropyl, or 2-ethoxyethyl. the hydroxyalkyl r1 has up to 4 carbon atoms in the alkyl part, which alkyl part may be branched or straight, and is, e.g. hydroxymethyl, 2-yhdroxyethyl, 3-hydroxypropyl, 1-hydroxyethyl, or 2-hydroxypropyl. the-alkyl r1 has up to 4 carbon atoms and may be branched or straight,. and is, e.g., methyl, ethyl, n.-propyl, isopropyl, n-butyl, sec. butyl, isobutyl, or tsrt. butyl. the halogen r2 is chloro, bromo, iodo, or fluoro,-preferab-ly chloro, or bromo. the alkyl r has up to 4 carbon atoms end may be straight, or branched, preferably straight, and is methyl, ethyl, or propyl, preferably methyi. the alkoxy r4 and r have up to 4 carbon atoms in the alkyl part thereof, and are, s.g., methoxy, ethoxy, isopropoxy, propoxy, or butoxy. preferably methoxy, and ethoxy. the alkyl r4 and r5 have up to 4 carbon atoms and are, e.g., methyl, ethyl, or isopropyl. the alkoxyalkyl r4 and r5 have up to 4 carbon atoms in each alkyl part, and are, e.g., methoxymethyl, methoxyethyl, ethoxyethyl, or isopropoxymethyl. n is an integer 0, 1, 2, or 3, preferably 0 and 1, whereby n is not zero when x is oxygen. x is oxygen, methylene, or carbonyl. r4 and r5 are bound in any position on the phenyl group, whereby preferably r4 is hydrogen and r5 is p-hydroxy, and r4 and r5 are both hydrogen. several compounds with well known adrenergie ss-receptor blocking activities, e.g., propranolol and alprenolol have membrane stabilizing properties as well. since b-blockers and membrane stabilizers (local anesthetics) exert antiarryhthmic effect on the heart by different mechanisms (vaughan-williams, e.m. in symposium on cardiac arrhythmias astra 19701, they are effec- tive against different types of arrhythmias. however, the b-blockers presently used in.the clinic exert their b-blocking activity in blood plasma concentrations of 50-100 nanograms/ml while they exert their membrane stabilizing effect
</DESCRIPTION>
<CLAIMS>
claims   1. a process for the preparation of new amines of the formula emi56.1       wherein r1 is selected from the group consisting of alkoxyalkyl, hydroxyalkyl and alkyl, r2 is selected from the group    3.   consisting of hydrogen and halogen, r  is selected from the    group consisting of hydrogen and alkyl, r4 and r5 are the same or different and are each selected from the group consisting of hydrogen, alkoxy, alkoxyalkyl, cyano, alkyl and hydroxy, n is an integer 0, 1, 2, or 3, and x is   -0-,    emi56.2       or -ch2- whereby n is not zero when x is oxygen characterized in that a) a compound of the formula ii emi56.3       wherein r1 and r2 have the same meanings given above, x1 is a hydroxy group and z is a reactive, esterified hydroxy group, or x1 and z together form an epoxy group, is allowed to react with an amine of the formula emi56.4       wherein r3, r4, r5, n and x have the same meanings as given above, or  b) a compound of the formula iii emi57.1       wherein r1, and r2 have the same meanings as given above,  is allowed to react with a compound of the formula emi57.2       wherein r3, r4, r5, n, x, and z have the same meanings as given above, c) a compound of the formula iv emi57.3       wherein r1, and r2 have the same meanings as given above, is allowed to react with a compound of formula v emi57.4       wherein z, x1, r3, r4, r5, n, and x have the same meanings as given above, or d) a compound of the formula iv emi57.5        wherein r1, and r2 have the same meanings as given above, is allowed to react with a compound of the formula vi emi58.1       wherein r3, r4, r5, n and x have the same meanings as given above, e) from a compound of the formula i wherein r1, r2, r3, r4, r5, n, and x have the same meanings as above, and which compound has a removable residue on the nitrogen atom of the amino group and/or has a removable residue on the hydroxy groups,  this residue is split off,   f]    a schiff's base of the formula viii or ix emi58.2       or a cyclic tautomer x related to the compound of formula ix emi58.3       wherein r1 r2, r3, r4, r5, n, and x have the same meanings  as above, except for the case when n - 0 and x   =    0, whereby the compounds ix and x may be present simultaneously, is reduced, or g) in a compound of the formula xi emi59.1       wherein r1, r2, r3, r4, r5, n, and x have the same meanings as above, the oxo group is reduced to a hydroxy group, h) in a compound of the formula xii emi59.2       wherein r2, r3,   r4-,    r5, n, and x have the same meanings as.   above and wherein yê is a residue transformable into   r1    haying the above meanings, xê is transformend into rú, or i) a compound of formula va emi59.3       wherein r1, r2, r3, n, and z have   ths    same meanings as above is allowed to react with a compound of formula iva emi59.4       wherein r4, and r5 have the same meanings as above, and x is d; or  k) in a compound corresponding to the one of formula i having an oxo group at a c-atom adjacent to the n-atom, this oxo group is reduced to two hydrogen atoms, and if desired, isomer mixtures obtained are separated into pure isomers, and/or racemates obtained are separated into optical antipodes, and/or free bases obtained are transformed into their therapeutically acceptable salt, or salts obtained are transformed into their free bases.   2. compounds of the formula i emi60.1       wherein r1 is selected from the group consisting of alkoxy   alkylt hydroxyalkyl,    r2 is selected from the group consisting of hydrogen and halogen, r3 is selected from the group con   slating    of hydrogen and alkyl, r4 and r5 are the same or different and are each selected from the group consisting of hydrogen, alkoxy, alkoxyalkyl, cyano, alkyl, and hydroxy, n is an integer 0, 1, 2, or 3, and x is -0-, emi60.2       or -ch2-, whereby n is not zero,when x is oxygen 3. a compound according to claim 2 in the form of a dextrorotating optical antipode.   4. a compound according to claim 2 in the form of a levorotating antipodes 5. a compound according to any one of claims 2-4 in the form of the free base.      5.    a compound according to any one of claims 2-4 in the form of a salt.     7. a compound according to any one of claims 2-4 in the of a therapeutically acceptable salt.   8. the method for treating symptoms and signs of arrhythmic conditions by stabilizing membranes of the heart and/or by blocking b-receptors of the heart by administering to mammals, including man, suffering from symptoms and signs of arrhythmic conditions a therapeutically effective amount of a compound of the general formula i emi61.1       wherein   r    is selected from the group consisting of alkoxyalkyl, hydroxyalkyl and alkyl, r2 is selected from the group consisting of hydrogen and halogen, r3 is selected from the group consisting of hydrogen and alkyl, r4 and    r5 are the same    or different and are each selected from the group consisting of hydrogen, alkoxy, alkoxyalkyl, cyano, alkyl and hydroxy, n is an integer 0,   1,    2, or 3, and x is -o-, emi61.2       or -ch2-,  or its therapeutically acceptable acid addition salts.      9..    pharmaceutical preparation which comprises as an active ingredient a therapeutically effective dose of at least one membrane stabilizing phenoxyhydroxypropylamine compound of the formula i emi61.3        wherein r1 is selected from the group consisting of   alkoxy-    alkyl, hydroxyalkyl and alkyl, r2 is selected from the group consisting of hydrogen and halogen, r3 is selected from the group consisting of hydrogen and alkyl, r4 and r5 are the same or different and are each selected from the group consisting of hydrogen, hydroxy, alkoxy, alkoxyalkyl, cyano and alkyl, n is an integer 0, 1, 2, or 3, and x is   -0,    emi62.1       or -ch2-, in association with a pharmaceutically acceptable carrier.    10. a pharmaceutical preparation according to claim 12, wherein the substituted phenoxy-hydroxypropylamine compound comprises 0,1 to 99% by weight of the preparation.  
</CLAIMS>
</TEXT>
</DOC>
